MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcoma by Serena Vella et al.
Vella et al. Clinical Epigenetics  (2015) 7:82 
DOI 10.1186/s13148-015-0107-zRESEARCH Open AccessMicroRNA-101 is repressed by EZH2 and its
restoration inhibits tumorigenic features in
embryonal rhabdomyosarcoma
Serena Vella1, Silvia Pomella2, Pier Paolo Leoncini1, Marta Colletti1, Beatrice Conti1, Victor E. Marquez3,
Antonio Strillacci4, Josep Roma5, Soledad Gallego5, Giuseppe M. Milano6, Maurizio C. Capogrossi2, Alice Bertaina6*,
Roberta Ciarapica2*† and Rossella Rota1*†Abstract
Background: Rhabdomyosarcoma (RMS) is a pediatric soft tissue sarcoma arising from myogenic precursors that
have lost their capability to differentiate into skeletal muscle. The polycomb-group protein EZH2 is a Lys27 histone
H3 methyltransferase that regulates the balance between cell proliferation and differentiation by epigenetically
silencing muscle-specific genes. EZH2 is often over-expressed in several human cancers acting as an oncogene. We
previously reported that EZH2 inhibition induces cell cycle arrest followed by myogenic differentiation of RMS cells of
the embryonal subtype (eRMS). MiR-101 is a microRNA involved in a negative feedback circuit with EZH2 in different
normal and tumor tissues. To that, miR-101 can behave as a tumor suppressor in several cancers by repressing EZH2
expression. We, therefore, evaluated whether miR-101 is de-regulated in eRMS and investigated its interplaying with
EZH2 as well as its role in the in vitro tumorigenic potential of these tumor cells.
Results: Herein, we report that miR-101 is down-regulated in eRMS patients and in tumor cell lines compared to their
controls showing an inverse pattern of expression with EZH2. We also show that miR-101 is up-regulated in eRMS cells
following both genetic and pharmacological inhibition of EZH2. In turn, miR-101 forced expression reduces EZH2 levels
as well as restrains the migratory potential of eRMS cells and impairs their clonogenic and anchorage-independent
growth capabilities. Finally, EZH2 recruitment to regulatory region of miR-101-2 gene decreases in EZH2-silenced eRMS
cells. This phenomenon is associated to reduced H3K27me3 levels at the same regulatory locus, indicating that EZH2
directly targets miR-101 for repression in eRMS cells.
Conclusions: Altogether, our data show that, in human eRMS, miR-101 is involved in a negative feedback loop with
EZH2, whose targeting has been previously shown to halt eRMS tumorigenicity. They also demonstrate that the
re-induction of miR-101 hampers the tumor features of eRMS cells. In this scenario, epigenetic dysregulations confirm
their crucial role in the pathogenesis of this soft tissue sarcoma.
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Rhabdomyosarcoma (RMS) is a soft tissue sarcoma that
accounts for 50 % of all soft tissue sarcomas in child-
hood. Two major histological RMS subtypes have been
identified, embryonal RMS (eRMS) and alveolar RMS
(aRMS) [1]. eRMS is the most frequent form (about 70–
80 %). RMS is believed to originate from immature
skeletal muscle cells that are unable to differentiate [2].
Consistently, the induction of differentiation is consid-
ered of therapeutic value [3, 4]. Our and other groups
have demonstrated that the histone methyltransferase
polycomb-group (PcG) protein enhancer of zeste
homologue 2 (EZH2) plays an important role in embry-
onal RMS tumorigenesis. EZH2 is the catalytic subunit
of the polycomb repressor complex 2 (PRC2) that,
through trimethylation of lysine 27 on histone H3
(H3K27me3), represses the transcription of specific tar-
get genes, thus preventing cell differentiation while pro-
moting proliferation. As a matter of fact, EZH2 inhibits
skeletal muscle differentiation by preventing the expres-
sion of miR-214 [5] while in turn, during myogenesis,
miR-214 directly targets EZH2 3′UTR for degradation
[6]. Regulatory feedback loops among EZH2 and micro-
RNAs have been identified among the mechanisms by
which EZH2 might sustain human tumorigenesis (for a
review, see Ref. [7]). In line with this evidence, miR-214
is under-expressed in eRMS and its re-induction leads to
myogenic differentiation [8]. Concordantly, we and others
recently reported that EZH2 is markedly expressed in
RMS primary specimens and cell lines compared to their
normal counterparts [9, 10] and that inhibition of EZH2
represents a promising pro-differentiation therapeutic
strategy in eRMS [11]. MiR-101 is a microRNA involved
in a feedback loop with EZH2 [12, 13]. In the last few
years, many studies have shown that miR-101 levels are
decreased in several tumors, including breast, lung, pros-
tate, ovarian, colon, and liver cancers, and that often miR-
101 exerts a tumor suppressive role [14–17]. Recently,
miR-101 has been shown to be induced during human
myoblast differentiation [18]. In the present work, since
EZH2 is abnormally up-regulated in eRMS, we sought to
evaluate whether miR-101 might be altered in this tumor.
Our results indicate that miR-101 is down-regulated in
eRMS primary samples and cell lines, and knockdown or
pharmacological inhibition of EZH2 up-regulates its levels.
The restoration of miR-101 expression is able to re-
duce proliferation and migration rates and to hamper
both the clonogenic and anchorage-independent cap-
abilities of eRMS tumor cells. Moreover, our data also
demonstrate that EZH2 inhibits miR-101 expression
in eRMS cells by direct gene targeting. Altogether,
these results suggest a negative feedback loop be-
tween miR-101 and EZH2 in eRMS cells and point
on miR-101 as a potential anticancer microRNA.Results
Inhibition of EZH2 restores miR-101 expression in
embryonal RMS
To ascertain whether miR-101 expression is compro-
mised in eRMS, we measured its levels along with those
of EZH2 in primary tumors. We noticed that miR-101
was expressed at very low levels in eRMS primary sam-
ples compared to normal muscle tissues as controls
(mean values: 0.23 ± 0.24 vs 5.7 ± 4.7, respectively)
(Fig. 1a, left). Conversely, in line with previous reports
[9, 10], EZH2 transcripts were markedly higher in the
same group of primary samples compared to controls
(mean values: 21.25 ± 8.86 vs 2.87 ± 1.31, respectively)
(Fig. 1a, right). Similarly, miR-101 expression was lower
in four eRMS cell lines (RD, RD18, JR1, RUCH2) than in
differentiated human skeletal muscle cells (SKMC DM)
(mean values 1.26 ± 0.49 vs 4.29 ± 0.55, respectively), in-
stead being comparable to the level of miR-101 in prolif-
erating skeletal myoblasts (SKMC GM) (Fig. 1b, left).
Moreover, EZH2 mRNA levels were 11.76 ± 2.23 higher
in the eRMS cell lines tested compared to SKMC
(Fig. 1b, right).
To analyze whether miR-101 expression was affected by
EZH2 modulation in eRMS, RD, JR1, and RD18 cell lines
were silenced for EZH2 using either a pool of oligo siRNAs
or oligo siRNA targeting the 5′UTR region of EZH2
mRNA, both previously validated (Additional file 1: Figures
S1A and S1B) [11], and the expression of miR-101 together
with that of other microRNAs known to be modulated by
EZH2 in RMS, such as miR-214 and miR-29b [3, 8], was
evaluated. As shown in Fig. 2a, EZH2 knockdown in eRMS
cells increases the expression of miR-29b, miR-214, and
miR-101 as soon as 72 h after siRNA transfection. Interest-
ingly, miR-101 was the most up-regulated in RD and RD18
cells, showing an about 4-fold increase compared with cells
transfected with a control non-targeting siRNA (CTR
siRNA). Similarly, treatment with DZNep, the prototype of
EZH2 inhibitors [11] which induces EZH2 degradation
(Additional file 1: Figure S1C), resulted in the up-
regulation of miR-101 with respect to cells treated with ve-
hicle (about 3.5-, 1.5-, and 5-fold increase in RD, JR1, and
RD18, respectively) (Fig. 2b). These results suggest that
miR-101 and EZH2 are inversely expressed in eRMS and
indicate EZH2 as a repressor of miR-101 in eRMS cells.
Over-expression of miR-101 restrains the proliferation
rate of embryonal RMS cells and reduces the endogenous
levels of EZH2
Next, we investigated in vitro whether miR-101 could
regulate EZH2 expression in eRMS cells, as reported for
other types of human cancers [12, 13]. We obtained an
about 6-fold increase of miR-101 expression by infecting
RD and JR1 cells with a GFP-coding retroviral vector ex-
pressing the pre-miR-101-2 form (pS-pre-miR-101) [19]
Fig. 1 MiR-101 and EZH2 levels are inversely expressed in embryonal rhabdomyosarcoma (RMS) patients and cell lines compared to their controls.
a Levels of mature miR-101 (left panel) and EZH2 (right panel) were determined by RT-qPCR in primary embryonal rhabdomyosarcoma (eRMS) samples
(black and grey bars, respectively) and in normal skeletal muscles (M1-4) used as control tissues (white bars). Values normalized to snoU6 or GAPDH
levels (respectively) were expressed as fold increase over M1 control tissue (1 arbitrary unit). b RT-qPCR of miR-101 (left panel) and EZH2 (right panel) in
eRMS cell lines (RD, RD18, RUCH2, and JR1; black and grey bars, respectively) and normal skeletal muscle cells (SKMC) cultured in either growth medium
(GM) or differentiating medium (DM) (as described in “Methods” section) were normalized to snoU6 or GAPDH levels, respectively, and were expressed
as fold increase over SKMC GM cells (1 arbitrary unit). Two independent measurements were done in duplicate
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of infection). Over-expression of miR-101 in eRMS cell
lines induced a 30 % down-regulation of EZH2 mRNA
and reduced protein levels compared to cells infected
with an empty retrovirus (pS-) (Fig. 3b,c). Moreover,
forced expression of miR-101 for 72 h resulted in the
up-regulation of protein levels of the cyclin-dependent
kinase inhibitor p21Cip1 (Fig. 3c). Therefore, we sought
to evaluate whether miR-101 ectopic over-expression
might affect eRMS cell proliferation. As reported in
Fig. 3d, miR-101 over-expression determined a cell cycle
G1/S blockade in RD cells whose percentage in G1
phase increased by 10 ± 3 % while in S and G2 phases
decreased by 13 ± 2 and 2 ± 0.8 %, respectively, com-
pared to pS- cells (Fig. 3d). These results are similar to
those previously published by our group on RD cells
after EZH2 silencing [11]. Interestingly, in JR1 cells in
which miR-101 has been over-expressed, we noticed a
cell cycle blockade in G2 phase (11.2 ± 1.8 % of in-
crease), compared to pS- cells (Fig. 3d). Of note, the
transcript levels of the oncogene N-Myc, a recognized
miR-101 target gene in cancer [20] and involved in the
aggressiveness of RMS [21], were markedly reduced inmiR-101-over-expressing RD cells (Additional file 3:
Figure S3A), confirming a targeted effect of miR-101
forced expression also in our setting. Altogether, these
data suggest a reciprocal regulation between EZH2 and
miR-101 in eRMS cells and indicate that miR-101 induc-
tion hampers their proliferative potential.
Over-expression of miR-101 restrains the migration of
embryonal RMS cells in vitro
The miR-101 tumor-suppressive activities have been also
related to its ability to negatively modulate tumor cell
migration [22–24]. Therefore, we decide to evaluate the
effects of miR-101 over-expression on the migratory po-
tential of eRMS cells in a wound healing assay. The 24-h
migration rate of pS-pre-miR-101-infected cells was
reduced of about 40 and 30 % for RD and JR1 cells, re-
spectively, compared to pS- cells (Fig. 4a,c). To deter-
mine whether EZH2 might be involved in their
migratory capability, eRMS cells were treated with
DZNep and the migration rate measured. As observed
for miR-101 over-expression, EZH2 pharmacological in-
hibition reduced eRMS cell migration (70 and 35 % re-
duction for RD and JR1 cells, respectively) (Fig. 4b,d). In
Fig. 3 MiR-101 over-expression reduces EZH2 levels and cell proliferation in eRMS cells. RT-qPCR analysis of mature a miR-101 and b EZH2 in RD and
JR1 cells 72 h post infection with pS-pre-miR-101 or control pS- retrovirus. Data were normalized using snoU6 and GAPDH levels respectively and
expressed as fold increase over control (pS-, 1 arbitrary unit). Columns, means; bars, SD. Results from three independent experiments are shown.
*P < 0.05, **P < 0.01, and ***P < 0.001 (Student’s t-test). c Western blots showing EZH2 and p21Cip1 levels in RD and JR1 cells 72 h post infection with
pS-pre-miR-101 or control pS- retrovirus. Total α-tubulin and GAPDH were used as loading controls. Representative of three independent experiments.
d Flow cytometry analysis after propidium iodide (PI) staining 72 h post infection with pS-pre-miR-101 or control pS- retrovirus on RD and JR1 cells
was performed. Ten thousand events per sample were acquired. The histogram depicts the fold change of cells in the G1, S, and G2 phases after
normalization to the percentage of GPF-positive cells for each sample. Results are means ± SD of two independent experiments
Fig. 2 Inhibition of EZH2 restores endogenous miR-101 levels in eRMS cells. a RT-qPCR analysis of mature forms of miR-214, miR-29b, and
miR-101 in RD, JR1, and RD18 cells 72 h post EZH2 siRNA transfection (RD were transfected with SMART pool siRNA EZH2 (asterisks), JR1 and
RD18 were transfected with siRNA targeting 5′-UTR of EZH2, see “Methods” section). Data normalized using snoU6 and expressed as fold
increase over a non-targeting siRNA (CTR siRNA, 1 arbitrary unit). Columns, means; bars, SD. Results from three independent experiments are shown.
*P < 0.05 (Student’s t-test). b MiR-101 level in RD, JR1, and RD18 cells daily treated for 72 h with either S-adenosyl-L-homocysteine hydrolase inhibitor
3-deazaneplanocin A (DZNep) (5 μM) or vehicle (i.e., water, referred as untreated condition: UN), normalized using snoU6 and expressed as fold
increase over UN (1 arbitrary unit). Columns, means; bars, SD. Results from three independent experiments are shown. *P < 0.05 (Student’s t-test)
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Fig. 4 MiR-101 forced expression as well as EZH2 pharmacological inhibition reduces eRMS cell migration. RD (a) and JR1 (c) cells were infected
with pS-pre-miR-101 or control pS- retrovirus. Twenty-four hours post-infection cells were seeded on inserts and lived to reach the confluence
for 48 h, when the inserts were removed. Cells were imaged at 0 and 24 h or 36 h after the insert removal. RD (b) and JR1 (d) were treated with
DZNep (5 μM) or vehicle (i.e., water, referred as untreated condition: UN) for 72 h and then inserts were removed and cells were imaged as in
(a) and (b). Representative phase contrast microscopy images of the migration assays at 0 and 24 h or 36 h after gap creation were shown.
Dashed lines indicate the boundary of the edges of the wound at 0 and 24 h or 36 h. The histograms depict the measurements of the total
area between the wound edges of the scratch from at least five random fields per scratch from two separate experiments, expressed as fold
change over control pS- (a and c, 1 arbitrary unit) or untreated (UN) (b and d, 1 arbitrary unit) samples. Columns, means; bars, SD. *P < 0.05
(Student’s t-test)
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pression reported in Fig. 2b, DZNep-treated RD cells
showed a down-regulation of the miR-101 target gene
N-Myc (Additional file 3: Figure S3B). Altogether, these
findings suggest that miR-101 and EZH2 regulate the
migration of eRMS cells in an opposite manner.
Over-expression of miR-101 reduces embryonal RMS cell
tumorigenic potential
As a negative regulator of proliferation and migration,
miR-101 is predicted to reduce tumorigenicity of eRMS
cells. To test whether miR-101 restoration might restrain
the clonogenic ability of eRMS cells, we performed colony
formation assays with RD and JR1 cells over-expressing
miR-101. As reported in Fig. 5a,b, miR-101 over-
expression reduced of 30 % of the ability to form colonies
in both RD and JR1 cells. Then, we evaluated the capability
of eRMS cell lines over-expressing miR-101 to grow as col-
onies in soft agar in an anchorage-independent manner, in-
dicative of malignant transformation and considered an
in vitro surrogate of the in vivo tumorigenicity testing. As
shown in Fig. 5c, d, miR-101 over-expression reduced the
formation of colonies in soft agar of about 50 % in bothRD and JR1 cells. Consistently, miR-101 over-expressing
RD18 cells showed 50 % EZH2 down-regulation associated
to cell cycle slow-down (5.4 ± 0.6 % increase of cells in the
G1 phase and 14 ± 2 and 3.4 ± 0.6 % decrease in S and G2
phases, respectively) and a more modest but significant re-
duction of colony formation of about 20 and 15 % on
either in culture dishes or soft agar (Additional file 4:
Figure S4). Taken together, these results indicate that res-
toration of miR-101 in eRMS exerts an antitumor effect
in vitro.
MiR-101 expression is directly repressed by EZH2 in
embryonal RMS
Since EZH2 down-regulation by either gene silencing or
pharmacological inhibition induces miR-101 up-regulation
(Fig. 2), we asked whether EZH2 might directly repress the
expression of miR-101 in eRMS. To test this hypothesis,
we performed chromatin immunoprecipitation (ChIP) ex-
periments upon EZH2 silencing in RD and JR1 cells testing
the occupancy of EZH2 on the promoter of miR-101-2 that
codifies for the miR-101 precursor pri-miR-101-2 from
which we derived the pre-miR-101-2 vector used for
over-expression experiments [25, 26]. As shown in two
Fig. 5 MiR-101 over-expression reduces colony formation and anchorage-independent growth capabilities in eRMS cells. RD (a) and JR1 (b) cells
were infected with pS-pre-miR-101 or control pS- retrovirus and, 72 h later, seeded to examine their clonogenic capability 2 weeks post seeding
(see “Methods” section). Histograms depict the number of colonies per plate from four independent experiments. Representative pictures of stained
colonies were shown on the right. RD (c) and JR1 (d) cells, infected as in (a) and (b), were seeded on soft agar for an anchorage-independent growth
assay. Colonies were visible. Histograms depict the number of colonies per plate after 4 weeks of incubation, calculated as means ± SD from four
independent experiments. Columns, means; bars, SD. *P < 0.05, **P < 0.01 (Student’s t-test)
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promoter of the miR-101-2 was occupied by EZH2 in
RD cells and upon EZH2 siRNA, in accordance with
EZH2 binding reduction to the promoter, also the level of
H3K27me3 resulted strikingly reduced. Similar results
were obtained in JR1 cells (Additional file 5: Figure S5).
EZH2 silencing induced the up-regulation of the pri-miR-
101-2 in RD (Fig. 6c) and in JR1 (Additional file 5:
Figure S5B) cells further corroborating the de-repression
effect of EZH2 depletion.
Discussion
In this study, we report, for the first time, that the micro-
RNA miR-101 is down-regulated in the most recurrent
variant of pediatric soft tissue sarcoma, i.e., the embryonal
rhabdomyosarcoma (eRMS), showing an inverse pattern
of expression with the histone methyltransferase EZH2.
This latter is a miR-101 target gene [12] and behaves as an
oncogene in eRMS [11, 27]. Moreover, we unveil a new
functional connection between miR-101 and EZH2 in this
tumor context. We demonstrate that knockdown of EZH2
by RNA silencing is sufficient to induce the up-regulation
of the endogenous levels of miR-101 in eRMS cells, thussuggesting that EZH2 might repress miR-101 in this
tumor type, as reported for other cancers [12, 25]. This
evidence was confirmed by the induction of miR-101
expression also in tumor cells in which EZH2 was
down-regulated through the treatment with DZNep, a
compound which works inducing EZH2 degradation
and already validated as an inhibitor of EZH2 by our
group on the same context [11]. The concomitant in-
duction in EZH2-depleted eRMS cells of the myogenic
microRNAs miR-214 and miR-29b, which have been pre-
viously involved in negative feedback loops with EZH2 in
myoblasts and RMS cells [3, 6, 8], confirms the disruption
of EZH2-dependent tumorigenic pathways. Interestingly,
while the up-regulation of miR-29b and miR-214 was
comparable among the three cell lines, the de-repression
of miR-101 appeared more modest in JR1 compared to
RD and RD18 cells, suggesting a context-dependent re-
sponse. Then, we show that retroviral-mediated forced
expression of a precursor of mature miR-101, which is
known to target EZH2 (pre-miR-101-2), in eRMS cells
results in the down-regulation of both mRNA and pro-
tein levels of EZH2. MiR-101 has been reported to
exert tumor suppressor functions in several human
Fig. 6 MiR-101 is directly targeted by EZH2 in RD cells. a, b Two independent ChIP assays on RD cells 72 h after EZH2 or CTR siRNA transfection
showing the recruitment of EZH2 and histone H3 trimethylation on Lys27 (H3K27me3) levels on miR-101-2 promoter region and MCK regulatory
regions. SMAD6 was the negative control gene. Rabbit IgG was used as a negative immunoprecipitation control. Histograms represent the
percent of immunoprecipitated material relative to input DNA of the two independent experiments. c mRNA levels (RT-qPCR) of pri-miR-101-2 in
RD cells 72 h after EZH2 siRNA treatment were normalized to GAPDH levels and expressed as fold increase over CTR siRNA. d Proposed model
depicting the interplay between EZH2 and miR-101 in both normal myogenic differentiation (left) and eRMS (right). In muscle cells, when
myogenesis is triggered, miR-101 is upregulated due to the lowering of EZH2 expression. Then, miR-101 directly inhibits EZH2 expression thus
enforcing its own expression, driving late skeletal muscle differentiation. In eRMS, this circuit is dysregulated due to EZH2 over-expression, which
leads to miR-101 down-regulation, thus maintaining the cells in an undifferentiated and proliferative state
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Therefore, on one hand, these results demonstrate that
miR-101 is able to regulate EZH2 levels also in the eRMS
tumor cell context and, on the other hand, they shed light
on the molecular mechanisms by which EZH2 could beup-regulated in eRMS. This scenario might suggest that,
in these tumor cells, EZH2 must be depleted in order to
allow miR-101 increase.
Coherently with the evidence that in eRMS cells (i)
EZH2 depletion inhibits proliferation (our previous
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regulates EZH2 (the present manuscript), we noticed a
reduction in the growth rate of miR-101 over-expressing
eRMS cells. The antiproliferative effect of miR-101
forced expression in these cells might be related to the
increase in p21Cip1 levels, which can regulate both G1 or
G2 cell cycle blockade, the same effect that we previously
observed upon EZH2 silencing [11]. However, this aspect
needs to be confirmed in future studies. Based on our ob-
servations, it can be hypothesized that low levels of miR-
101 in eRMS contribute to the up-regulation of EZH2,
which sustains tumor cell proliferation. Consistently with
this hypothesis, EZH2 genetic of pharmacologic inhibition
induces the blockade of eRMS cell proliferation and the
appearance of a muscle-like phenotype [11].
This finding is in line with the evidence that (i) miR-
101 expression increases in human SKMC induced to
differentiate, i.e., cell cycle arrested, which confirms the
recent observations obtained through microRNA profil-
ing [18], and, in turn, (ii) EZH2 expression decreases in
the same context, as previously reported by us and
others [5, 6, 32].
However and interestingly, even if miR-101 increases
in RD cells depleted of EZH2, its forced induction is un-
able to promote terminal differentiation in vitro and my-
osin heavy chain (MHC)-positive myotube-like fiber
formation (data not shown). Nevertheless, the myogenic
role of miR-101 has not yet been defined. As a matter of
fact, although miR-101 was barely detectable in murine
myoblasts in proliferation, its expression was not modu-
lated during myogenic cell differentiation [6]. Clearer is
the role of miR-101 in inhibiting tumor cell migration
[23, 33]. Consistently with its tumor suppressor proper-
ties, when over-expressed miR-101 significantly reduced
eRMS cell motility in vitro. Similar results were obtained
by pharmacologically down-regulating EZH2, once again
confirming the opposite functional roles of EZH2 and
miR-101 in these tumor cells. Our results also unveil an
inhibitory effect of miR-101 on the tumorigenic potential
of eRMS cells by blocking both the clonogenic capability
and the anchorage-independent features typical of malig-
nant cells. Finally, the evidence that EZH2 binds the
miR-101 gene promoter highlighted a direct effect of the
oncogene on miR-101 expression further supporting a
feedback loop involving the two molecular players. In
summary, our findings indicate that EZH2 represses
miR-101 expression and that, in turn, miR-101 can re-
strain EZH2 expression in eRMS (Fig. 6d).
Conclusions
Results presented here now unveil miR-101 low expres-
sion as a new epigenetic dysregulation in eRMS and high-
light its tumor suppressor role in this tumor type. We
show that miR-101 is directly repressed by EZH2, a keyplayer whose targeting has been suggested as a powerful
epigenetic therapy to halt eRMS tumorigenicity. Although
the precise role of miR-101 in myogenesis still requires in-
depth investigation, results presented here indicate that a
fine tuning regulation of the levels of EZH2 and miR-101
is critical for defying miR-101/EZH2 functional balance in
eRMS, thus reinforcing the concept that epigenetic dys-
regulation is a key event in the pathogenesis of this tumor.
Methods
Cell lines
RD (embryonal RMS, eRMS) cell lines were obtained
from American Type Culture Collection (Rockville,
MD). RD18, JR1, and RUCH2 (all eRMS) cell lines were
a gift of C. Ponzetto, G. Grosveld, and J. Roma, respect-
ively. Normal human skeletal muscle cells (SkMC; myo-
blasts) were obtained from PromoCell (Promocell
GmbH, Heidelberg, Germany).
Cell line culture
RD, RUCH2, and RD18 cells were cultured in DMEM
high glucose while JR1 cells were cultured in RPMI 1640
(both from Invitrogen Corp., Carlsbad, CA, USA). All
RMS cell lines were cultured in medium supplemented
with 10 % FCS, 1 % glutamine, and 1 % penicillin-
streptomycin at 37 °C in a humidified atmosphere of 5 %
CO2/95 % air. Human myoblasts, SkMC (C-12530 Promo-
Cell GmbH, Heidelberg, Germany), were maintained in
proliferating condition in PromoCell Cell Growth Medium
(GM) supplemented with growth factors (C-23060 and
C23160, PromoCell GmbH, Heidelberg, Germany). A hu-
man skeletal muscle differentiation model was obtained
treating SkMC myoblasts for 14 days with a differentiating
medium (DM) with appropriate supplements (C-23161
and C-39366, PromoCell GmbH, Heidelberg, Germany).
Several aliquots of the first culture for each RMS cell line
were stored in liquid nitrogen at −80 °C for subsequent as-
says. Each aliquot was passaged for a maximum of
5 months. ATCC genomics core utilizes scientific know-
ledge and technical expertise to design and perform nu-
merous authentication and confirmatory assays (such as
DNA barcoding and species identification, quantitative
gene expression and transcriptome analyses) for ATCC
collections (see www.lgcstandards-atcc.org). The DSMZ
authenticates all human cell lines prior to accession by
DNA typing, while the species-of-origin of animal cell lines
are confirmed by PCR analysis (“speciation”). Independent
evidence of authenticity is also provided by cytogenetic
and immunophenotypic tests of characterization which are
particularly informative among human tumor cell lines
which form the bulk of the collection (see www.dsmz.de).
Five different batches of SkMC were obtained, each from a
different healthy donor, and immediately cultured and
assayed in specific experiments as reported. The cell
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herence rate, and cell viability; immunohistochemical tests
for cell-type-specific markers are carried out for each lot
and, furthermore, the capacity to differentiate into multi-
nucleated syncytia is routinely checked for each lot (see
www.promocell.com).
RMS primary tissues
RMS and control tissues were obtained from the Clinical
Oncohematology Division, Ospedale Pediatrico Bambino
Gesù in Rome, Italy, and Oncohematology Department,
Vall d’Hebron Hospital in Barcelona, Spain, after ap-
proval of the respective ethical committees (EC of Ospe-
dale Pediatrico Bambino Gesù, Rome; CEIC of Vall
d’Hebron Hospital). Clinicopathological characteristics
of the cohort are reported in Additional file 6: Table S1.
We confirm that written informed consent from the
donor or the next of kin was obtained for use of these
samples in research.
Real-time RT-quantitative PCR
Total RNA was extracted using TRIzol (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s proto-
col and inspected by agarose gel electrophoresis. Reverse
transcription was performed using the Improm-II Reverse
Transcription System (Promega, Madison, WI, USA). The
expression levels were measured by real-time RT-qPCR for
the relative quantification of the gene expression as de-
scribed [9]. TaqMan gene assay (Applied Biosystems, Life
Technologies, Carlsbad, CA, USA) for EZH2 (Hs010
16789_m1), N-Myc (Hs00232074_m1), and pri-miR-101-2
(Hs03303387_pri) were used. The samples were normalized
according to the glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) mRNA (Hs99999905_m1) levels.
Reverse transcription for miRNAs was performed
using the TaqMan MicroRNA Reverse Transcription Kit
with specific miRNA primers (Applied Biosystems). Taq-
Man microRNA assays (Applied Biosystems) were used
for relative quantification of the mature miR-101 (hsa-
miR-101; 002253), miR-29b (hsa-miR-29b; 0000413), and
miR-214 (hsa-miR-214; 002293) expression levels, as
described [9]. snoU6 snRNA (001093) was used for
normalization. An Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems) was used for the
measurements. The expression fold change was calculated
by the 2-ΔΔCt method for each of the reference genes [34].
At least two independent amplifications were performed
for each probe, with triplicate samples.
Western blotting
Western blotting was performed on whole-cell lysates as
previously described [35, 36]. Total protein extraction
was performed by homogenizing cells in RIPA lysis buf-
fer (50 mM Tris pH 7.5, 150 mM NaCl, 1 % Triton X-100, 1 mM EDTA, 1 % sodium deoxycholate and phos-
phatases 1 % cocktail protease inhibitors, 0.5 mM sodium
orthovanadate). Lysates were sonicated and incubated on
ice for 30 min and centrifugated at 12,000 g for 20 min at
4 °C. Supernatants were then quantified with BCA Protein
Assay Kit (Pierce, Life Technologies) according to the
manufacturer’s protocol and then boiled in reducing SDS
sample buffer (200 mM Tris–HCl [pH 6.8], 40 % glycerol,
20 % β-mercaptoethanol, 4 % sodium dodecyl sulfate, and
bromophenol blue); and 30 μg of protein lysate per lane
was run through 7 and 12 % SDS-PAGE gels, and then
transferred to Hybond ECL membranes (Amersham, GE
HEALTHCARE BioScience Corporate Piscataway, NJ,
USA). Membranes were blocked for 1 h in 5 % non-fat
dried milk in Tris-buffered saline (TBS) and incubated
overnight with the appropriate primary antibody at 4 °C.
Membranes were then washed in TBS and incubated with
the appropriate secondary antibody. Both primary and
secondary antibodies were diluted in 5 % non-fat dried
milk in TBS. Detection was performed by ECL Western
Blotting Detection Reagents or by ECL Plus Western Blot-
ting Detection Reagents (Amersham, GE HEALTHCARE
BioScience Corporate Piscataway, NJ, USA). Antibodies
against EZH2 (612666; Transduction Laboratories TM,
BD, Franklin Lakes, NJ), p21 (C-19) (sc-397; Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), α-tubulin (NB
100–92249, Novus Biologicals), and GAPDH (D16H11;
Cell Signaling Technology Inc., Beverly, MA, USA) were
used. All secondary antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). All the antibodies were
used in accordance with the manufacturer’s instruc-
tions. Images of radiograms were acquired through the
HP Precision ScanJet 5300 C Scanner (Hewlett-Packard,
Palo Alto, CA, USA).
Transient RNA interference transfection and
pharmacological treatments
Cells were seeded in 6-well/plates (150,000 cells/well)
and grown up to 30 % confluence. After 24 h, cells were
transfected with ON-TARGETplus SMART pool siRNA
against EZH2 (L-004218-00) or non-targeting siRNA
(control; D-001206-13) (both from Dharmacon, Thermo
Fisher Scientific, Lafayette, CO, USA) or with a siRNA
targeting the 5′-UTR of EZH2 mRNA with the following
sequence 5′-CGGTGGGACTCAGAAGGCA-3′ and
non-targeting siRNA as control (5′-UGGUUUACAUG
UCGACUAA-3′) (both from Sigma, St Louis, MO,
USA) [32] at 100 nM final concentration each round
using Oligofectamine (Invitrogen, Carlsbad, CA), ac-
cording to manufacturer’s recommendations. After 24 h,
cells were transfected again and siRNA effectiveness was
validated by Western blotting and RT-qPCR 48 h after
the first silencing. For pharmacological treatments, cells
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(DZNep) or water as vehicle for 48 h or 72 h.
Virus production and cell infections
pSuper.retro vector expressing the endogenous human
miR-101-2 precursor (pS-pre-miR-101) and its negative
control (pS-, empty) have been already described [17, 19].
These vectors were transfected into Phi-NX (“Phoenix”)
packaging cell line to produce ecotropic retroviral super-
natants. Phoenix cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) supplemented with 10 %
FCS. The day before transfection, Phoenix cells were
seeded in 10-cm dishes (5 × 106 cells/dish) in order to
reach 85–90 % confluence at the time of transfection.
Cells were transfected with 10 μg of viral vector DNA
using Lipofectamine 2000 transfection reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s in-
structions. After 6 h of incubation at 37 °C, transfection
medium was replaced with 7 ml of complete medium con-
taining 10 % FCS. At 48 h after transfection, culture
medium was filtered through a 0.45-mm filter and the
viral supernatant was used for RD, JR1, and RD18 cell in-
fection after addition of 8 mg/ml of polybrene (Sigma, St
Louis, MO, USA). After infection, RD, JR1, and RD18 cells
were incubated at 37 °C in 5 % CO2. After 8 h of incuba-
tion, the medium was changed with new viral superna-
tants and incubated overnight. Then, the medium was
changed with a fresh medium and cells were allowed to
recover for 24 h at 37 °C in 5 % CO2. Infection efficiency
was examined under a fluorescence microscope (not
shown) and determined by flow cytometry for the expres-
sion of the green fluorescent protein (GFP). MiR-101 ex-
pression levels in RD, JR1, and RD18 cells infected with
the control (−pS) and miR-101 expressing vector (pS-pre-
miR-101) was analyzed by real-time polymerase chain re-
action (RT-qPCR).
Cell cycle assays
After two rounds of infection with the control (−pS) and
miR-101 expressing vector (pS-pre-miR-101), RD, JR1,
and RD18 cells were analyzed by flow cytometry as re-
ported [37]. Briefly, cells were harvested by trypsiniza-
tion 72 h after infection, washed in ice-cold PBS, fixed
in 50 % PBS and 50 % acetone/methanol (1:4 v/v) for at
least 1 h, and, after removing alcoholic fixative, stained
in the dark with a solution containing 50 μg/ml propi-
dium iodide (PI) and 50 μg/ml RNase (Sigma Chemical
Co., St Louis, MO, USA) for 30 min at room
temperature. The stained cells were analyzed for cell
cycle by fluorescence-activated cell sorting using a
FACSCantoII equipped with a FACSDiva 6.1 CellQuest™
software (Becton Dickinson Instrument, San Josè, CA,
USA). The percentage of cells in G0/G1, S, and G2/M
phases was expressed as relative change compared topS-infected cells, and normalized to the percentage of
GPF-positive cells as measured by flow cytometry.
Cell wound healing assay
Wound healing assay was performed with the Ibidi
Culture-Insert (Ibidi®) as manufacturer’s instruction.
Briefly, cell suspensions of RD and JR1 cells infected
with pS-pre-miR-101 and pS- or treated with DZNep/
Vehicle for 72 h were prepared (3–4 × 105 cells/ml) and
70 μl were applied into each well. Cells were incubated
at 37 °C and 5 % CO2 for 24 h. After appropriate cell at-
tachment, culture inserts were gently removed, fresh
medium was added, and images were captured immedi-
ately (day 0) and 24 and 36 h later with a Leica DMi8
Inverted Microscope. Cell migration was quantitatively
assessed measuring the entire area of the scratches by
ImageJ software (Wayne Rasband, NIH, Bethesda, MD,
USA; http://rsb.info.nih.gov/ij/). The results were ob-
tained from measurements of the total area of the
scratch between the wound edges per scratch from two
separate experiments for each cell line, expressed as fold
change over either control ones.
Colony formation assay
After 72 h of infection with retroviral pS-pre-miR-101
and pS-, RD, JR1, and RD18 cells were assayed for the
clonogenic survival. A total of 5 × 102 or 10 × 102 cells
were seeded in 6 multi-well plates with 2 mL of DMEM
(10 % FBS). Medium was refreshed every 2 days, and after
14 days, cells were fixed and stained with Diff-Quik®
(Medion Diagnostic AG 460.053) as manufacturer’s in-
struction. Colonies containing >50 cells were counted.
Triplicate assays were carried out in four independent
experiments.
Soft agar colony formation assay
After 72 h of infection with retroviral pS-pre-miR-101 and
pS-, RD, JR1, and RD18 cells were assayed for their cap-
acity to form colonies in soft agar. A total of 5 × 103, 10 ×
103, or 20 × 103 cells were suspended in DMEM (10 %
FBS) containing 0.35 % agar (NuSieve GTG Agarose).
Cells were seeded on a layer of 0.7 % agar in DMEM
(10 % FBS) in 6 multi-well plates. Medium was refreshed
every 2 days. On week 4, colonies were counted by micro-
scopic inspection. Colony numbers were normalized by
dividing the number of colonies by the number of total
units (colonies + single cells). Triplicate assays were car-
ried out in four independent experiments.
Chromatin immunoprecipitation (ChIP)
ChIP assay was performed as previously described [11, 32]
with minor modifications. Briefly, chromatin was cross-
linked in 1 % formaldehyde for 15 min at room
temperature and quenched by addition of glycine at
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temperature before being placed on ice. Cells were washed
twice with ice-cold PBS containing 1 mM PMSF and 1X
protease inhibitors, resuspended in ice-cold cell lysis buffer
(10 mM Tris–HCl pH 8, 10 mM NaCl, 0.2 % NP-40,
1 mM PMSF, and 1X protease inhibitors), and incubated
on ice for 30 min. After centrifugation at 4000 rpm for
5 min at 4 °C, nuclei were resuspended in ice-cold nuclear
lysis buffer (50 mM TrisHCl pH 8.1; 10 mM EDTA; 1 %
SDS, 1 mM PMSF, and 1X protease inhibitors) and left
overnight at 4 °C on a rotating platform. Chromatin was
then sonicated to an average fragment size of 200–300 bp
using a Diagenode (water bath) and diluted ten times with
IP dilution buffer (16.7 mM Tris–HCl pH 8.1, 167 mM
NaCl, 1.2 mM EDTA, 0.01 %SDS, 1.1 % Triton X-100,
1 mM PMSF, and 1X protease inhibitors). Diluted chroma-
tin was pre-cleared using protein G-agarose magnetic
beads (Invitrogen) for 1 h at 4 °C and incubated with the
corresponding antibodies overnight at 4 °C. The following
antibodies were used: anti-trimethyl Lysine 27 histone H3
(Cell Signaling, #9733) and anti-EZH2 (Cell Signaling,
#5246). Immunoprecipitated chromatin was recovered by
incubation with protein G-agarose magnetic beads (Invi-
trogen, Carlsbad, CA, USA) for 2 h at 4 °C. Beads were
washed twice with low-salt washing buffer (20 mM Tris–
HCl pH 8, 2 mM EDTA, 1 % Triton X-100, 0.1 % SDS,
150 mM NaCl), twice with high-salt washing buffer
(20 mM Tris–HCl pH 8, 2 mM EDTA, 1 % Triton X-100,
0.1 % SDS, 500 mM NaCl), and twice with TE before incu-
bating them with elution buffer (10 mM Tris–HCl pH 8,
1 mM EDTA, 1 % SDS). Cross-linking was then reverted
overnight at 65 °C and samples were treated with protein-
ase K for 2 h at 42 °C. The DNA was finally purified by
phenol: chloroform extraction in the presence of 0.4 M
LiCl and ethanol precipitated. Purified DNA was resus-
pended in 50 μl of water. Real-time PCR was performed on
input samples and equivalent amounts of immunoprecipi-
tated material with the SYBR Green Master Mix (Applied
Biosystems, Life Technologies, Carlsbad, CA, USA). Primer
sequences are available on request.
Statistical analysis
The data were presented as the means ± SD. Compari-
sons were made between the means from at least two
independent experiments repeated in triplicate. The
statistical differences were analyzed using Student’s t-test.
P values < 0.05 were considered statistically significant.Additional files
Additional file 1: Figure S1. EZH2 levels in eRMS cells after EZH2
down-regulation. Western blot showing the reduction of EZH2 levels in RD
cells after 48 h of transfection with EZH2 pool siRNA(*) or a non-targeting
control (CTR) siRNA (A), RD, JR1, and RD18 after 48 h of transfection withEZH2 5′UTR EZH2 siRNA or a non-targeting control (CTR) siRNA (B), or
DZNep treatment (5 μM) or vehicle (i.e., water, referred as untreated
condition: UN) (C). Total α-tubulin or GAPDH were used as loading controls.
Representative of three independent experiments.
Additional file 2: Figure S2. Infection efficiency in eRMS cells.
Representative cytofluorometric plots show the level of GFP fluorescence
in RD, JR1, and RD18 cells infected with pS-pre-miR-101 or control
pS- retrovirus for 72 h, and the percentage of GFP positivity is reported
inside the plots within the right upper quadrant Q2 and in the tables on
the right.
Additional file 3: Figure S3. RT-qPCR analysis of N-Myc in RD cells after
miR-101 over-expression or EZH2 inhibition. (A) RT-qPCR analysis of
N-Myc in RD cells infected with pS-pre-miR-101 and control pS- retrovirus.
Data were normalized to GAPDH levels and expressed as fold increase
over control (pS-, 1 arbitrary unit). (B) RD cells were treated with DZNep
(5 μM) or vehicle (i.e., water, referred as untreated condition: UN). Data
were normalized to GAPDH levels and expressed as fold increase over
UN (1 arbitrary unit). Columns, means; bars, SD. Results from three
independent experiments are shown. *P < 0.05 (Student’s t-test).
Additional file 4: Figure S4. miR-101 over-expression reduces EZH2
levels, cell proliferation, anchorage-independent growth, and cell proliferation
in RD18 cells. qRT-PCR analysis of mature miR-101 (A) and EZH2 (B) 72 h post
infection with pS-pre-miR-101 or control pS- retrovirus. Data were normalized
using snoU6 and GAPDH levels respectively and expressed as fold increase
over control (pS-, 1 arbitrary unit). Columns, means; bars, SD. Results from
three independent experiments are shown. *P < 0.05 (Student’s t-test). (C)
Western blot showing EZH2 levels 72 h post infection with pS-pre-miR-101 or
control pS- retrovirus. GAPDH was used as a loading control. Representative
of three independent experiments. (D) Flow cytometry analysis after
propidium iodide (PI) staining 72 h post infection with pS-pre-miR-101 or
control pS- retrovirus was performed. Ten thousand events per sample were
acquired. The histogram depicts the fold change of cells in the G1, S, and G2
phases after normalization using percentage of GPF-positive cells for each
sample. Results are means ± SD of two independent experiments. (E)
Proliferation assay shows a growth reduction after 72 h of infection with
pS-pre-miR-101 vs control pS- retrovirus. Colonies were visible after 2 weeks
(see “Methods” section) of incubation and values represent the number of
colonies per plate calculated as means ± SD from four independent
experiments. Representative colony formation pictures were shown. Columns,
means; bars, SD. *P< 0.05 (Student’s t-test). (F) Cells infected with pS-pre-miR-
101 and control pS- retrovirus were examined for anchorage-independent
growth by soft agar assay. Colonies were visible after 4 weeks (see “Methods”
section) of incubation. The histograms represent the number of colonies
per plate as means ± SD from four independent experiments.
Columns, means; bars, SD. *P < 0.05 (Student’s t-test).
Additional file 5: Figure S5. Signal-specific recruitment of EZH2 onto
the miR-101-2 promoter in JR1 cells after EZH2 down-regulation. (A) ChIP
assays on JR1 cells 72 h after EZH2 or CTR siRNA transfection showing
the recruitment of EZH2 and the levels of histone H3 trimethylation on
Lys27 (H3K27me3) on miR-101-2, MCK, and SMAD6 (as negative control)
regulatory regions. Normal rabbit IgG were used as negative control.
Graphs represent the percent of immunoprecipitated material relative to
input DNA. (B) mRNA levels (RT-qPCR) of pri-miR-101-2 in JR1 cells 48 h
after EZH2 siRNA treatment were normalized to GAPDH levels and
expressed as fold increase over CTR siRNA.
Additional file 6: Table S1. Clinical and histopathologic data of
rhabdomyosarcoma tumor.Abbreviations
RMS: rhabdomyosarcoma; eRMS: embryonal rhabdomyosarcoma;
SKMC: skeletal muscle cells; GM: growth factor-supplemented medium;
EZH2: enhancer of zeste of homologue 2; PRC2: polycomb repressor
complex 2; GAPDH: glyceraldehyde 3-phosphate dehydrogenase;
MCK: muscle creatine kinase; SMAD6: small mother against decapentaplegic
6; siRNA: small interfering RNA; DZNep: S-adenosylhomocysteine hydrolase
inhibitor 3-deazaneplanocin A; SD: standard deviation; RT-qPCR: quantitative
real-time polymerase chain reaction; PI: propidium iodide.
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